Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Staphylococcus is a **genus of Gram-positive cocci** that typically form clusters resembling grape bunches. Members are non-motile, non-spore-forming facultative anaerobes found commonly on human skin and mucous membranes. The most clinically significant species are *Staphylococcus aureus*, which can cause severe infections such as wound infections, sepsis, pneumonia, food poisoning, toxic shock syndrome and more; *S. epidermidis*, an opportunistic pathogen especially relevant in immunocompromised patients or those with indwelling devices; and *S. saprophyticus*, associated with urinary tract infections. The term "Staphylococcus genus bacteria" refers to an entire group containing over fifty recognized species rather than a single molecular target or protein—thus it is **not considered a therapeutic target** like receptors or enzymes would be.[1][2][3] Instead, individual proteins within these bacteria may serve as drug targets. Some staphylococci produce toxins contributing to disease severity. A major public health concern is the emergence of antibiotic-resistant strains such as methicillin-resistant *S. aureus* (**MRSA**) and vancomycin-resistant *S. aureus* (**VRSA**), which complicate treatment options.[4] Diagnosis relies on culture characteristics and biochemical tests including coagulase activity.[5] Treatment depends on antibiotic susceptibility profiles but may involve penicillins/cephalosporins unless resistance dictates alternatives like vancomycin or linezolid.[6] Because "Staphylococcus genus bacteria" refers to an entire bacterial group—not a single molecule—it does **not fit standard definitions for drug targets**, making this entry incorrect if used where only molecular targets are appropriate. > “Assignment of a strain to the genus Staphylococcus requires it to be a Gram-positive coccus that forms clusters... All species grow in the presence of bile salts.” [1] > > “There are currently 53 recognised species... The staphylococci most frequently associated with human infection are S. aureus, S. epidermidis and S.saprophyticus.” [2] > > “Of significance to humans are various strains... While S.epidermidis is a mild pathogen...strains of S.aureus are major agents...” [4]
Not directly applicable at the genus level; for drugs targeting staphylococci in general: - Inhibition of cell wall synthesis (β-lactams like penicillins/cephalosporins/vancomycin) - Inhibition of protein synthesis (linezolid)[4][6]
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcus genus bacterium.